Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens

Sergio Ricci, Luca Galli, Aldo Chioni, Mauro Iannopollo, Andrea Antonuzzo, Francesco Francesca, Vittorio Vocaturo, Cesare Selli, Cinzia Orlandini, PierFranco Conte

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

BACKGROUND. The objective of this study was to evaluate the efficacy and toxicity of gemcitabine plus epirubicin in previously untreated patients with advanced urothelial carcinoma who were not eligible for cisplatin-based regimens. METHODS. Patients with advanced urothelial carcinoma and at least one of the following characteristics were eligible: impaired renal function (creatinine clearance <60 mL per minute), an Eastern Cooperative Oncology Group performance status (PS) ≥ 2, and age ≥ 75 years. The treatment included epirubicin 70 mg/m2 as an intravenous bolus on Day 1 and gemcitabine 1000 mg/m2 over 30 minutes on Days 1 and 8 of a 21-day cycle. RESULTS. Thirty-eight patients entered the study, and a total of 152 cycles were administered, with a median of 4 cycles per patient (range, 1-6 cycles per patient). The following Grade 3-4 hematologic toxicities were reported (percent of cycles): neutropenia, 22.4%; anemia, 11.2%; and thrombocytopenia, 6.5%. No cardiac, renal, or hepatic toxicities were observed. Dose intensities of epirubicin and gemcitabine were 19.6 mg/m2 per week (84%) and 532.2 mg/m2 per week (80%), respectively. There were 2 complete responses (5.3%), 13 partial responses (34.2%), 11 patients with stable disease (28.9%), and 12 patients with progressive disease (31.6%), for an overall response rate of 39.5% (95% confidence interval, 25.1-55.1). The median progression free survival (PFS) and overall survival (OS) rates were 4.8 months and 8.0 months, respectively. The 1-year survival rate was 38%, and the median PFS and OS were 6.4 months and 16.4 months, respectively, in patients with PS 0-1. Thirty patients were symptomatic: Seventeen patients (56.7%) achieved a complete response, and 5 patients (16.7%) achieved a partial symptomatic response. CONCLUSIONS. At the doses given in this study, gemcitabine and epirubicin had a good tolerability profile with interesting activity in patients with advanced urothelial carcinoma who were not fit for cisplatin-based regimens.

Original languageEnglish
Pages (from-to)1444-1450
Number of pages7
JournalCancer
Volume95
Issue number7
DOIs
Publication statusPublished - Oct 1 2002

Fingerprint

gemcitabine
Epirubicin
Platinum
Carcinoma
Cisplatin
Disease-Free Survival
Survival Rate
Kidney

Keywords

  • Epirubicin
  • Gemcitabine
  • Unfit
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens. / Ricci, Sergio; Galli, Luca; Chioni, Aldo; Iannopollo, Mauro; Antonuzzo, Andrea; Francesca, Francesco; Vocaturo, Vittorio; Selli, Cesare; Orlandini, Cinzia; Conte, PierFranco.

In: Cancer, Vol. 95, No. 7, 01.10.2002, p. 1444-1450.

Research output: Contribution to journalArticle

Ricci, S, Galli, L, Chioni, A, Iannopollo, M, Antonuzzo, A, Francesca, F, Vocaturo, V, Selli, C, Orlandini, C & Conte, P 2002, 'Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens', Cancer, vol. 95, no. 7, pp. 1444-1450. https://doi.org/10.1002/cncr.10860
Ricci, Sergio ; Galli, Luca ; Chioni, Aldo ; Iannopollo, Mauro ; Antonuzzo, Andrea ; Francesca, Francesco ; Vocaturo, Vittorio ; Selli, Cesare ; Orlandini, Cinzia ; Conte, PierFranco. / Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens. In: Cancer. 2002 ; Vol. 95, No. 7. pp. 1444-1450.
@article{72a4dbbf24184bc7a77a8cb34a169830,
title = "Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens",
abstract = "BACKGROUND. The objective of this study was to evaluate the efficacy and toxicity of gemcitabine plus epirubicin in previously untreated patients with advanced urothelial carcinoma who were not eligible for cisplatin-based regimens. METHODS. Patients with advanced urothelial carcinoma and at least one of the following characteristics were eligible: impaired renal function (creatinine clearance <60 mL per minute), an Eastern Cooperative Oncology Group performance status (PS) ≥ 2, and age ≥ 75 years. The treatment included epirubicin 70 mg/m2 as an intravenous bolus on Day 1 and gemcitabine 1000 mg/m2 over 30 minutes on Days 1 and 8 of a 21-day cycle. RESULTS. Thirty-eight patients entered the study, and a total of 152 cycles were administered, with a median of 4 cycles per patient (range, 1-6 cycles per patient). The following Grade 3-4 hematologic toxicities were reported (percent of cycles): neutropenia, 22.4{\%}; anemia, 11.2{\%}; and thrombocytopenia, 6.5{\%}. No cardiac, renal, or hepatic toxicities were observed. Dose intensities of epirubicin and gemcitabine were 19.6 mg/m2 per week (84{\%}) and 532.2 mg/m2 per week (80{\%}), respectively. There were 2 complete responses (5.3{\%}), 13 partial responses (34.2{\%}), 11 patients with stable disease (28.9{\%}), and 12 patients with progressive disease (31.6{\%}), for an overall response rate of 39.5{\%} (95{\%} confidence interval, 25.1-55.1). The median progression free survival (PFS) and overall survival (OS) rates were 4.8 months and 8.0 months, respectively. The 1-year survival rate was 38{\%}, and the median PFS and OS were 6.4 months and 16.4 months, respectively, in patients with PS 0-1. Thirty patients were symptomatic: Seventeen patients (56.7{\%}) achieved a complete response, and 5 patients (16.7{\%}) achieved a partial symptomatic response. CONCLUSIONS. At the doses given in this study, gemcitabine and epirubicin had a good tolerability profile with interesting activity in patients with advanced urothelial carcinoma who were not fit for cisplatin-based regimens.",
keywords = "Epirubicin, Gemcitabine, Unfit, Urothelial carcinoma",
author = "Sergio Ricci and Luca Galli and Aldo Chioni and Mauro Iannopollo and Andrea Antonuzzo and Francesco Francesca and Vittorio Vocaturo and Cesare Selli and Cinzia Orlandini and PierFranco Conte",
year = "2002",
month = "10",
day = "1",
doi = "10.1002/cncr.10860",
language = "English",
volume = "95",
pages = "1444--1450",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens

AU - Ricci, Sergio

AU - Galli, Luca

AU - Chioni, Aldo

AU - Iannopollo, Mauro

AU - Antonuzzo, Andrea

AU - Francesca, Francesco

AU - Vocaturo, Vittorio

AU - Selli, Cesare

AU - Orlandini, Cinzia

AU - Conte, PierFranco

PY - 2002/10/1

Y1 - 2002/10/1

N2 - BACKGROUND. The objective of this study was to evaluate the efficacy and toxicity of gemcitabine plus epirubicin in previously untreated patients with advanced urothelial carcinoma who were not eligible for cisplatin-based regimens. METHODS. Patients with advanced urothelial carcinoma and at least one of the following characteristics were eligible: impaired renal function (creatinine clearance <60 mL per minute), an Eastern Cooperative Oncology Group performance status (PS) ≥ 2, and age ≥ 75 years. The treatment included epirubicin 70 mg/m2 as an intravenous bolus on Day 1 and gemcitabine 1000 mg/m2 over 30 minutes on Days 1 and 8 of a 21-day cycle. RESULTS. Thirty-eight patients entered the study, and a total of 152 cycles were administered, with a median of 4 cycles per patient (range, 1-6 cycles per patient). The following Grade 3-4 hematologic toxicities were reported (percent of cycles): neutropenia, 22.4%; anemia, 11.2%; and thrombocytopenia, 6.5%. No cardiac, renal, or hepatic toxicities were observed. Dose intensities of epirubicin and gemcitabine were 19.6 mg/m2 per week (84%) and 532.2 mg/m2 per week (80%), respectively. There were 2 complete responses (5.3%), 13 partial responses (34.2%), 11 patients with stable disease (28.9%), and 12 patients with progressive disease (31.6%), for an overall response rate of 39.5% (95% confidence interval, 25.1-55.1). The median progression free survival (PFS) and overall survival (OS) rates were 4.8 months and 8.0 months, respectively. The 1-year survival rate was 38%, and the median PFS and OS were 6.4 months and 16.4 months, respectively, in patients with PS 0-1. Thirty patients were symptomatic: Seventeen patients (56.7%) achieved a complete response, and 5 patients (16.7%) achieved a partial symptomatic response. CONCLUSIONS. At the doses given in this study, gemcitabine and epirubicin had a good tolerability profile with interesting activity in patients with advanced urothelial carcinoma who were not fit for cisplatin-based regimens.

AB - BACKGROUND. The objective of this study was to evaluate the efficacy and toxicity of gemcitabine plus epirubicin in previously untreated patients with advanced urothelial carcinoma who were not eligible for cisplatin-based regimens. METHODS. Patients with advanced urothelial carcinoma and at least one of the following characteristics were eligible: impaired renal function (creatinine clearance <60 mL per minute), an Eastern Cooperative Oncology Group performance status (PS) ≥ 2, and age ≥ 75 years. The treatment included epirubicin 70 mg/m2 as an intravenous bolus on Day 1 and gemcitabine 1000 mg/m2 over 30 minutes on Days 1 and 8 of a 21-day cycle. RESULTS. Thirty-eight patients entered the study, and a total of 152 cycles were administered, with a median of 4 cycles per patient (range, 1-6 cycles per patient). The following Grade 3-4 hematologic toxicities were reported (percent of cycles): neutropenia, 22.4%; anemia, 11.2%; and thrombocytopenia, 6.5%. No cardiac, renal, or hepatic toxicities were observed. Dose intensities of epirubicin and gemcitabine were 19.6 mg/m2 per week (84%) and 532.2 mg/m2 per week (80%), respectively. There were 2 complete responses (5.3%), 13 partial responses (34.2%), 11 patients with stable disease (28.9%), and 12 patients with progressive disease (31.6%), for an overall response rate of 39.5% (95% confidence interval, 25.1-55.1). The median progression free survival (PFS) and overall survival (OS) rates were 4.8 months and 8.0 months, respectively. The 1-year survival rate was 38%, and the median PFS and OS were 6.4 months and 16.4 months, respectively, in patients with PS 0-1. Thirty patients were symptomatic: Seventeen patients (56.7%) achieved a complete response, and 5 patients (16.7%) achieved a partial symptomatic response. CONCLUSIONS. At the doses given in this study, gemcitabine and epirubicin had a good tolerability profile with interesting activity in patients with advanced urothelial carcinoma who were not fit for cisplatin-based regimens.

KW - Epirubicin

KW - Gemcitabine

KW - Unfit

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0036784466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036784466&partnerID=8YFLogxK

U2 - 10.1002/cncr.10860

DO - 10.1002/cncr.10860

M3 - Article

C2 - 12237912

AN - SCOPUS:0036784466

VL - 95

SP - 1444

EP - 1450

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -